Tatva Chintan Share Price Surges 7% as Q2FY27 Net Profit Rises 116% to ₹21.5 Crore

Tatva Chintan Pharma Chem Limited reported a 116% year-on-year increase in consolidated net profit to ₹21.5 crore in Q2FY27, compared with ₹9.9 crore in Q2FY26, as per exchange filings dated October 19, 2026.  

Revenue from operations rose 76% to ₹217.3 crore from ₹123.5 crore in the year-ago quarter. The company recorded its highest-ever quarterly turnover during the September quarter. 

Total income increased 76% to ₹219.1 crore, while profit before tax more than doubled to ₹28.9 crore from ₹13.7 crore a year earlier. 

Tatva Chintan Pharma's EBITDA and Operating Costs 

EBITDA, excluding other income, increased 83% to ₹40.7 crore from ₹22.2 crore in Q2FY26. The EBITDA margin stood at 19%, against 18% in the corresponding quarter last year. Earnings per share rose to ₹9.17 from ₹4.24. 

The company reported higher raw materials and freight costs during the quarter. Short supplies of certain solvents pushed their prices up by 60% to 100%. Freight rates also increased by more than 100% on certain routes in the US and Europe. 

Tatva Chintan said both cost pressures were showing signs of easing and expected conditions to normalise during Q3FY27. 

Tatva Chintan Pharma's Business Updates 

Structured Directing Agents (SDA) continued to contribute to revenue, with sales benefiting from the implementation of EURO 7 emission standards.  

In its Electrolyte Salts and Solutions business, hybrid-battery applications were progressing towards commercialisation, while additional products were being scaled up for energy storage. 

The company also reported sales from recently commercialised agrochemical products and an initial contribution from a pharmaceutical product. Its five semiconductor chemical products remained at different stages of development, validation, and customer qualification. 

Tatva Chintan Pharma H1FY27 Earnings Results 

For the six months ended September 2026, revenue from operations increased 60% to ₹384.4 crore from ₹240.4 crore. EBITDA rose 85% to ₹73 crore, while net profit increased 126% to ₹37.4 crore from ₹16.6 crore. The net profit margin improved to 9.7% from 6.9%. 

Read More: Delta Corp Share Price in Focus; Posts ₹106.41 Crore Net Loss in Q2FY27! 

Tatva Chintan Pharma Chem Share Price Performance  

As of 21 October 2026, 9:15 am, Tatva Chintan Pharma Chem share price was trading at ₹2,026.40, a 7% increase from the previous closing price. 

Conclusion 

Tatva Chintan reported higher revenue and net profit in Q2FY27, although solvent prices and freight charges increased operating costs. The company expects these cost pressures to ease in the following quarter. 

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions. 

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.